Defendants in Tuschl-I IP Suit Cast Doubt on Claims of Pending Patent Issuance

In doing so, the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology, and the University of Massachusetts have all asked that the court reject Alnylam Pharmaceuticals and Max Planck's request for an order blocking any Tuschl-I patent issuance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.